Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05352815




Registration number
NCT05352815
Ethics application status
Date submitted
24/04/2022
Date registered
29/04/2022
Date last updated
25/06/2024

Titles & IDs
Public title
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec
Scientific title
A 52 Week Study Comparing the Efficacy and Safety of Once Weekly IcoSema and Once Weekly Insulin Icodec, Both Treatment Arms With or Without Oral Anti Diabetic Drugs, in Participants With Type 2 Diabetes Inadequately Controlled With Daily Basal Insulin.
Secondary ID [1] 0 0
U1111-1260-8259
Secondary ID [2] 0 0
NN1535-4591
Universal Trial Number (UTN)
Trial acronym
COMBINE 1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Diabetes Mellitus, Type 2 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - IcoSema
Treatment: Drugs - Insulin icodec

Experimental: IcoSema -

Active comparator: Insulin icodec -


Treatment: Drugs: IcoSema
Participants will receive once weekly IcoSema subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks.

Treatment: Drugs: Insulin icodec
Participants will receive once weekly Insulin icodec subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change in glycated haemoglobin (HbA1c)
Timepoint [1] 0 0
From baseline week 0 (V2) to week 52 (V54)
Secondary outcome [1] 0 0
Change in body weight
Timepoint [1] 0 0
From baseline week 0 (V2) to week 52 (V54)
Secondary outcome [2] 0 0
Number of clinically significant hypoglycaemic episodes (level 2) (below 3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3)
Timepoint [2] 0 0
From baseline week 0 (V2) to week 57 (V56)

Eligibility
Key inclusion criteria
Key inclusion criteria

1. Male or female and age above or equal to 18 years at the time of signing informed consent.
2. Diagnosed with type 2 diabetes mellitus 180 days or more before screening.
3. HbA1c of 7.0 10.0% (53.0 85.8 mmol/mol) (both inclusive) as assessed by central laboratory on the day of screening.
4. Treated with once daily or twice daily basal insulin (neutral protamine hagedorn insulin, insulin degludec, insulin detemir, insulin glargine 100 units/mL, or insulin glargine 300 units/mL) 20- 80 units/day for 90 days or more before screening. Short term bolus insulin treatment for a maximum of 14 days before screening is allowed, as is prior insulin treatment for gestational diabetes. The treatment can be with or without any of the following anti diabetic drugs with stable doses for 90 days or more before screening:

* Metformin
* Sulfonylureas (a)
* Meglitinides (glinides) (a)
* DPP 4 inhibitors (a)
* Sodium glucose co transporter 2 inhibitors
* Alpha glucosidase inhibitors
* Thiazolidinediones
* Marketed oral combination products only including the products listed above.
5. Body mass index (BMI) below or equal to 40.0 kg/m^2. (a) Sulfonylureas, meglitinides (glinides) and DPP 4 inhibitors must be discontinued at randomisation.

Key exclusion criteria

1. Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method.
2. Anticipated initiation or change in concomitant medication (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or systemic corticosteroids).
3. Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening.
4. Any episodes (as declared by the participant or in the medical records.) of diabetic ketoacidosis within 90 days before screening.
5. Presence or history of pancreatitis (acute or chronic) within 180 days before screening.
6. Any of the following: Myocardial infarction, stroke, hospitalization for unstable angina pectoris or transient ischaemic attack within 180 days before screening.
7. Chronic heart failure classified as being in New York Heart Association Class IV at screening.
8. Recurrent severe hypoglycaemic episodes within the last year (12 months) as judged by the investigator.
9. Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days before screening or in the period between screening and randomisation. Pharmacological pupil dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/06/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
23/04/2024
Sample size
Target
Accrual to date
Final
1291
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,VIC
Recruitment hospital [1] 0 0
Holdsworth House Clinical Research - Darlinghurst
Recruitment hospital [2] 0 0
Novatrials - Kotara
Recruitment hospital [3] 0 0
Illawarra Diabetes Service Clinical Trials & Research Unit - Wollongong
Recruitment hospital [4] 0 0
Royal Brisbane and Women's Hospital - Herston
Recruitment hospital [5] 0 0
Southern Adelaide Diabetes & Endocrine Services - Oaklands Park
Recruitment hospital [6] 0 0
Launceston General Hospital - Launceston
Recruitment hospital [7] 0 0
Barwon Health (The Geelong Hospital) - Geelong
Recruitment hospital [8] 0 0
The Alfred Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
2289 - Kotara
Recruitment postcode(s) [3] 0 0
2500 - Wollongong
Recruitment postcode(s) [4] 0 0
4029 - Herston
Recruitment postcode(s) [5] 0 0
5046 - Oaklands Park
Recruitment postcode(s) [6] 0 0
7250 - Launceston
Recruitment postcode(s) [7] 0 0
3220 - Geelong
Recruitment postcode(s) [8] 0 0
3004 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Iowa
Country [9] 0 0
United States of America
State/province [9] 0 0
Kansas
Country [10] 0 0
United States of America
State/province [10] 0 0
Kentucky
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Michigan
Country [15] 0 0
United States of America
State/province [15] 0 0
Minnesota
Country [16] 0 0
United States of America
State/province [16] 0 0
Missouri
Country [17] 0 0
United States of America
State/province [17] 0 0
Nebraska
Country [18] 0 0
United States of America
State/province [18] 0 0
Nevada
Country [19] 0 0
United States of America
State/province [19] 0 0
New Hampshire
Country [20] 0 0
United States of America
State/province [20] 0 0
New Mexico
Country [21] 0 0
United States of America
State/province [21] 0 0
New York
Country [22] 0 0
United States of America
State/province [22] 0 0
North Carolina
Country [23] 0 0
United States of America
State/province [23] 0 0
Ohio
Country [24] 0 0
United States of America
State/province [24] 0 0
Tennessee
Country [25] 0 0
United States of America
State/province [25] 0 0
Texas
Country [26] 0 0
United States of America
State/province [26] 0 0
Virginia
Country [27] 0 0
Belgium
State/province [27] 0 0
Bonheiden
Country [28] 0 0
Belgium
State/province [28] 0 0
Brussel
Country [29] 0 0
Belgium
State/province [29] 0 0
Bruxelles
Country [30] 0 0
Belgium
State/province [30] 0 0
Edegem
Country [31] 0 0
Belgium
State/province [31] 0 0
Kortrijk
Country [32] 0 0
Belgium
State/province [32] 0 0
Leuven
Country [33] 0 0
Bulgaria
State/province [33] 0 0
Burgas
Country [34] 0 0
Bulgaria
State/province [34] 0 0
Kyustendil
Country [35] 0 0
Bulgaria
State/province [35] 0 0
Pleven
Country [36] 0 0
Bulgaria
State/province [36] 0 0
Plovdiv
Country [37] 0 0
Bulgaria
State/province [37] 0 0
Sofia
Country [38] 0 0
China
State/province [38] 0 0
Anhui
Country [39] 0 0
China
State/province [39] 0 0
Beijing
Country [40] 0 0
China
State/province [40] 0 0
Chongqing
Country [41] 0 0
China
State/province [41] 0 0
Guangdong
Country [42] 0 0
China
State/province [42] 0 0
Hebei
Country [43] 0 0
China
State/province [43] 0 0
Henan
Country [44] 0 0
China
State/province [44] 0 0
Jiangsu
Country [45] 0 0
China
State/province [45] 0 0
Shandong
Country [46] 0 0
China
State/province [46] 0 0
Shanghai
Country [47] 0 0
China
State/province [47] 0 0
Tianjin
Country [48] 0 0
Croatia
State/province [48] 0 0
Grad Zagreb
Country [49] 0 0
Croatia
State/province [49] 0 0
Osjecko - Baranjska Županija
Country [50] 0 0
Croatia
State/province [50] 0 0
Osijek
Country [51] 0 0
Croatia
State/province [51] 0 0
Pula
Country [52] 0 0
Croatia
State/province [52] 0 0
Rijeka
Country [53] 0 0
Finland
State/province [53] 0 0
Kuopio
Country [54] 0 0
Finland
State/province [54] 0 0
Raisio
Country [55] 0 0
Finland
State/province [55] 0 0
Tampere
Country [56] 0 0
Finland
State/province [56] 0 0
Turku
Country [57] 0 0
Finland
State/province [57] 0 0
Ähtäri
Country [58] 0 0
India
State/province [58] 0 0
Gujarat
Country [59] 0 0
India
State/province [59] 0 0
Kerala
Country [60] 0 0
India
State/province [60] 0 0
Madhya Pradesh
Country [61] 0 0
India
State/province [61] 0 0
Maharashtra
Country [62] 0 0
India
State/province [62] 0 0
Punjab
Country [63] 0 0
India
State/province [63] 0 0
Tamil Nadu
Country [64] 0 0
India
State/province [64] 0 0
Telangana
Country [65] 0 0
India
State/province [65] 0 0
Telengana
Country [66] 0 0
India
State/province [66] 0 0
New Delhi
Country [67] 0 0
Italy
State/province [67] 0 0
BA
Country [68] 0 0
Italy
State/province [68] 0 0
Catanzaro
Country [69] 0 0
Italy
State/province [69] 0 0
Chiavari (genova)
Country [70] 0 0
Italy
State/province [70] 0 0
Milano
Country [71] 0 0
Japan
State/province [71] 0 0
Fukushima, Japan
Country [72] 0 0
Japan
State/province [72] 0 0
Hokkaido, Japan
Country [73] 0 0
Japan
State/province [73] 0 0
Kanagawa, Japan
Country [74] 0 0
Japan
State/province [74] 0 0
Kumamoto, Japan
Country [75] 0 0
Japan
State/province [75] 0 0
Miyazaki
Country [76] 0 0
Japan
State/province [76] 0 0
Arakawa-ku, Tokyo
Country [77] 0 0
Japan
State/province [77] 0 0
Chiba-shi, Chiba
Country [78] 0 0
Japan
State/province [78] 0 0
Fukuoka-shi, Fukuoka
Country [79] 0 0
Japan
State/province [79] 0 0
Hokkaido
Country [80] 0 0
Japan
State/province [80] 0 0
Kumamoto
Country [81] 0 0
Japan
State/province [81] 0 0
Saga-shi, Saga
Country [82] 0 0
Japan
State/province [82] 0 0
Tokyo
Country [83] 0 0
Japan
State/province [83] 0 0
Yokohama-shi, Kanagawa
Country [84] 0 0
Korea, Republic of
State/province [84] 0 0
Chungcheongnam-do
Country [85] 0 0
Korea, Republic of
State/province [85] 0 0
Gyeonggi-do
Country [86] 0 0
Korea, Republic of
State/province [86] 0 0
Seongnam-si
Country [87] 0 0
Korea, Republic of
State/province [87] 0 0
Seoul
Country [88] 0 0
Korea, Republic of
State/province [88] 0 0
Wonju
Country [89] 0 0
Mexico
State/province [89] 0 0
Nuevo León
Country [90] 0 0
Mexico
State/province [90] 0 0
Aguascalientes
Country [91] 0 0
Mexico
State/province [91] 0 0
Mexico City
Country [92] 0 0
Norway
State/province [92] 0 0
Bodø
Country [93] 0 0
Norway
State/province [93] 0 0
Drammen
Country [94] 0 0
Norway
State/province [94] 0 0
Hamar
Country [95] 0 0
Norway
State/province [95] 0 0
Oslo
Country [96] 0 0
Norway
State/province [96] 0 0
Trondheim
Country [97] 0 0
Poland
State/province [97] 0 0
Lubelski
Country [98] 0 0
Poland
State/province [98] 0 0
Gdansk
Country [99] 0 0
Poland
State/province [99] 0 0
Lublin
Country [100] 0 0
Poland
State/province [100] 0 0
Warszawa
Country [101] 0 0
Portugal
State/province [101] 0 0
Almada
Country [102] 0 0
Portugal
State/province [102] 0 0
Aveiro
Country [103] 0 0
Portugal
State/province [103] 0 0
Braga
Country [104] 0 0
Portugal
State/province [104] 0 0
Lisboa
Country [105] 0 0
Portugal
State/province [105] 0 0
Matosinhos
Country [106] 0 0
Portugal
State/province [106] 0 0
Vila Nova de Gaia
Country [107] 0 0
Puerto Rico
State/province [107] 0 0
Bayamon
Country [108] 0 0
Puerto Rico
State/province [108] 0 0
Manati
Country [109] 0 0
Romania
State/province [109] 0 0
Bucurestii
Country [110] 0 0
Romania
State/province [110] 0 0
Maramures
Country [111] 0 0
Romania
State/province [111] 0 0
Brasov
Country [112] 0 0
Romania
State/province [112] 0 0
Iasi
Country [113] 0 0
Romania
State/province [113] 0 0
Satu-Mare
Country [114] 0 0
Romania
State/province [114] 0 0
Suceava
Country [115] 0 0
Russian Federation
State/province [115] 0 0
Russia
Country [116] 0 0
Russian Federation
State/province [116] 0 0
Arkhangelsk
Country [117] 0 0
Russian Federation
State/province [117] 0 0
Ekaterinburg
Country [118] 0 0
Russian Federation
State/province [118] 0 0
Irkutsk
Country [119] 0 0
Russian Federation
State/province [119] 0 0
Kursk
Country [120] 0 0
Russian Federation
State/province [120] 0 0
Saint-Petersburg
Country [121] 0 0
Russian Federation
State/province [121] 0 0
Saratov
Country [122] 0 0
Serbia
State/province [122] 0 0
Belgrade
Country [123] 0 0
South Africa
State/province [123] 0 0
Gauteng
Country [124] 0 0
South Africa
State/province [124] 0 0
KwaZulu-Natal
Country [125] 0 0
South Africa
State/province [125] 0 0
North West
Country [126] 0 0
South Africa
State/province [126] 0 0
Western Cape
Country [127] 0 0
South Africa
State/province [127] 0 0
Alberton
Country [128] 0 0
Taiwan
State/province [128] 0 0
Changhua City
Country [129] 0 0
Taiwan
State/province [129] 0 0
Taichung
Country [130] 0 0
Taiwan
State/province [130] 0 0
Tainan City
Country [131] 0 0
Taiwan
State/province [131] 0 0
Taipei city
Country [132] 0 0
Turkey
State/province [132] 0 0
Altindag
Country [133] 0 0
Turkey
State/province [133] 0 0
Adana
Country [134] 0 0
Turkey
State/province [134] 0 0
Ankara
Country [135] 0 0
Turkey
State/province [135] 0 0
Istanbul
Country [136] 0 0
Turkey
State/province [136] 0 0
Tekirdag

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novo Nordisk A/S
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin icodec taken once a week in people with type 2 diabetes.

The study will look at how well IcoSema controls blood sugar level in people with type 2 diabetes compared to insulin icodec.

Participants will either get IcoSema or insulin icodec. Which treatment participants get is decided by chance. IcoSema and insulin icodec are both new medicines that doctors cannot prescribe.

Participants will get IcoSema or insulin icodec, which participants must inject once a week with a pen, which has a small needle, in a skin fold in the thigh, upper arm, or stomach.

The study will last for about 1 year and 1 month. Participants will have 21 clinic visits, 31 phone/video calls with the study doctor, and 4 contacts with the site that can either be clinic visits or phone/video calls At 11 clinic visits participants will have blood samples taken. At 7 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit.

Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.

Not applicable for China: Participants will be asked to wear a sensor that measures their blood sugar level all the time during a 5 week period at the end of the study.
Trial website
https://clinicaltrials.gov/study/NCT05352815
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Transparency (dept. 2834)
Address 0 0
Novo Nordisk A/S
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05352815